Sam Brusco, Associate Editor03.13.23
Teleflex released new research from controlled and real-world studies of its prostatic urethral lift (PUL) procedure using its UroLift system to treat men with benign prostatic hyperplasia (BPH). The research was presented at the 38th Annual European Association of Urology (EAU) Congress.
Results underscored the benefits of earlier intervention with respect to durability, symptom improvement, and sexual function.
“These important new analyses show that, whether compared to other interventions or medication, the UroLift System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms,” Jacqueline Welch, VP of global clinical and scientific operations at Teleflex told the press.
The results shared from the over 330 PUL subjects in the controlled setting show PUL using UroLift was durable in most subjects at one and five years. It was also demonstrated that earlier treatment in the disease continuum positively affects quality of life outcomes.
Patient experience results of obstructive median lobe (OML) subjects treated with PUL showed that compared to transurethral resection of the prostate (TURP) done in lateral lobes, UroLift system OML subjects had superior quality of recovery and preservation of ejaculatory function.
“The research presented at EAU reinforces the UroLift System as an effective and durable BPH solution, backed by meaningful quality of life data that support a superior patient experience,” said Steven Gange, M.D., F.A.C.S., of Summit Urology Group and Associate Medical Director of the Teleflex Interventional Urology Business Unit. “The results from these studies emphasize the value of the UroLift System in successfully treating BPH symptoms, enabling rapid recovery, preserving sexual function, and improving patients’ overall quality of life.”
Results underscored the benefits of earlier intervention with respect to durability, symptom improvement, and sexual function.
“These important new analyses show that, whether compared to other interventions or medication, the UroLift System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms,” Jacqueline Welch, VP of global clinical and scientific operations at Teleflex told the press.
The results shared from the over 330 PUL subjects in the controlled setting show PUL using UroLift was durable in most subjects at one and five years. It was also demonstrated that earlier treatment in the disease continuum positively affects quality of life outcomes.
Patient experience results of obstructive median lobe (OML) subjects treated with PUL showed that compared to transurethral resection of the prostate (TURP) done in lateral lobes, UroLift system OML subjects had superior quality of recovery and preservation of ejaculatory function.
“The research presented at EAU reinforces the UroLift System as an effective and durable BPH solution, backed by meaningful quality of life data that support a superior patient experience,” said Steven Gange, M.D., F.A.C.S., of Summit Urology Group and Associate Medical Director of the Teleflex Interventional Urology Business Unit. “The results from these studies emphasize the value of the UroLift System in successfully treating BPH symptoms, enabling rapid recovery, preserving sexual function, and improving patients’ overall quality of life.”